Australia appears to be welcome potentially transformative medication for weight issues: Retatrutide. This new dual compound – targeting on both GLP-1 and GIP receptors – has promising efficacy in clinical studies, pointing to considerable reductions in weight. While regulatory clearance hasn't occurred with the Therapeutic Goods Administration